Next Article in Journal
Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy
Next Article in Special Issue
1,25(OH)2D3 Differently Affects Immunomodulatory Activities of Mesenchymal Stem Cells Depending on the Presence of TNF-α, IL-1β and IFN-γ
Previous Article in Journal
Near-Infrared Spectroscopy Monitoring in Cardiac and Noncardiac Surgery: Pairwise and Network Meta-Analyses
Previous Article in Special Issue
Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis—A Phase I Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 8
Issue 12
10.3390/jcm8122207
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton’s Jelly, an Extraembryonic Source

by
Caroline Laroye
1,2,3,
Mélanie Gauthier
1,2,3,
Hélène Antonot
1,
Véronique Decot
1,2,
Loïc Reppel
1,2,3 and
Danièle Bensoussan
1,2,3,*
1
CHRU de Nancy, Unité de Thérapie Cellulaire et banque de tissus, 54500 Vandoeuvre-lès-Nancy, France
2
CNRS, UMR 7365, 54500 Vandoeuvre-lès-Nancy, France
3
Faculté de Pharmacie, Université de Lorraine, 54000 Nancy, France
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(12), 2207; https://doi.org/10.3390/jcm8122207
Submission received: 21 November 2019 / Revised: 4 December 2019 / Accepted: 9 December 2019 / Published: 14 December 2019
(This article belongs to the Special Issue Mesenchymal Stem/Stromal Cells in Immunity and Disease)
Browse Figures
Versions Notes

Abstract

Many clinical trials report mesenchymal stem/stromal cells (MSCs) efficacy in various indications. Therefore, standardization of MSC production becomes necessary. MSC properties are impacted by tissue origin, especially if they are from extraembryonic tissue or adult sources. For this reason, we evaluated the impact of MSC tissue origin on production. Methods: Three productions of MSC from Wharton’s Jelly (WJ) or from bone marrow (BM) were performed according to good manufacturing practice. The identity (phenotype, differentiation, and clonogenic capacities), safety (karyotype, telomerase activity, sterility, and donor qualification), and functionality (viability, mixed lymphocyte reaction) of each cell batch were analyzed. Results: Slight differences between MSC sources were observed for phenotype, telomerase activity, and clonogenic capacities. Conclusion: Both sources have made it possible to quickly and easily obtain clinical grade MSC. However, as availability of the source is thought to be essential, WJ seems more advantageous than BM.
Keywords: mesenchymal stem/stromal cells; bone marrow; Wharton’s jelly; good manufacturing practice mesenchymal stem/stromal cells; bone marrow; Wharton’s jelly; good manufacturing practice

Share and Cite

MDPI and ACS Style

Laroye, C.; Gauthier, M.; Antonot, H.; Decot, V.; Reppel, L.; Bensoussan, D. Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton’s Jelly, an Extraembryonic Source. J. Clin. Med. 2019, 8, 2207. https://doi.org/10.3390/jcm8122207

AMA Style

Laroye C, Gauthier M, Antonot H, Decot V, Reppel L, Bensoussan D. Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton’s Jelly, an Extraembryonic Source. Journal of Clinical Medicine. 2019; 8(12):2207. https://doi.org/10.3390/jcm8122207

Chicago/Turabian Style

Laroye, Caroline, Mélanie Gauthier, Hélène Antonot, Véronique Decot, Loïc Reppel, and Danièle Bensoussan. 2019. "Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton’s Jelly, an Extraembryonic Source" Journal of Clinical Medicine 8, no. 12: 2207. https://doi.org/10.3390/jcm8122207

APA Style

Laroye, C., Gauthier, M., Antonot, H., Decot, V., Reppel, L., & Bensoussan, D. (2019). Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton’s Jelly, an Extraembryonic Source. Journal of Clinical Medicine, 8(12), 2207. https://doi.org/10.3390/jcm8122207

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop